Skip to main content

Table 3 Predictive biomarkers detected by array CGH with associated approved or experimental relevant therapeutics

From: Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer

Biomarker

Positive cases

Description

Target class

Therapeutics

CCNE1 Amp

N=4

Cyclin E1

Cell cycle inhibitor

BMS-387032, flavopiridol, seliciclib, P1446A-05

ERBB2 Amp

N=1

HER2

Kinase

Lapatinib, trastuzumab, neratinib

KRAS Amp

N=1

v-Ki-ras2

Kinase

PD 0325901, GSK1120212, AS703026, MSC1936369B, AZD6244, ARRY-438162

BRCA1 Del

N=7

Early onset breast cancer gene 1

Poly ADP Ribose Polymerase inhibitors (PARP)

AZD2281, ABT-888, MK4827

BRCA2 Del

N=3

Early onset breast cancer gene 2

Poly ADP Ribose Polymerase inhibitors (PARP)

AZD2281, ABT-888, MK4827

Bi-allelic PTEN Del

N=1

 

PI3K\AKT\mTOR inhibitors

Rapamycin

  1. *Therapeutics table adapted from The Cancer Genome Atlas Network: Integrated genomic analyses of ovarian carcinoma [8].
  2. **Amp = amplification; Del =deletion.